Traws Pharma Delays Influenza Study as UK Regulator Seeks More Data
NEWTOWN, PA — Traws Pharma (NASDAQ: TRAW) said this week it is preparing additional toxicology data requested by U.K. regulators, delaying the planned launch of a Phase 2a human influenza …
Traws Pharma Delays Influenza Study as UK Regulator Seeks More Data Read More